2023
Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma
Dolgalev I, Zhou H, Murrell N, Le H, Sakellaropoulos T, Coudray N, Zhu K, Vasudevaraja V, Yeaton A, Goparaju C, Li Y, Sulaiman I, Tsay J, Meyn P, Mohamed H, Sydney I, Shiomi T, Ramaswami S, Narula N, Kulicke R, Davis F, Stransky N, Smolen G, Cheng W, Cai J, Punekar S, Velcheti V, Sterman D, Poirier J, Neel B, Wong K, Chiriboga L, Heguy A, Papagiannakopoulos T, Nadorp B, Snuderl M, Segal L, Moreira A, Pass H, Tsirigos A. Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma. Nature Communications 2023, 14: 6764. PMID: 37938580, PMCID: PMC10632519, DOI: 10.1038/s41467-023-42327-x.Peer-Reviewed Original ResearchConceptsTumor-adjacent tissuesDisease progressionInflammatory signatureEarly-stage lung adenocarcinoma patientsSuccessful surgical resectionLong-term patientsInflammatory gene signatureLung adenocarcinoma patientsStrongest clinical predictorsNon-immune cellsNormal lung tissuesAdjacent normal tissuesCancer Genome AtlasSurgical resectionClinical predictorsClinical outcomesAdenocarcinoma patientsPredictive biomarkersWorse outcomesLung tissueDisease outcomeLung adenocarcinomaHigh riskSingle-cell transcriptomic analysisGene signature
2020
Expanding the Role of Immunotherapy to Limited-Stage SCLC
Punekar S, Shum E. Expanding the Role of Immunotherapy to Limited-Stage SCLC. Journal Of Thoracic Oncology 2020, 15: 1806-1808. PMID: 33246593, DOI: 10.1016/j.jtho.2020.09.021.Peer-Reviewed Original Research